Helius Medical Technologies, Inc.
HSM.TO
Toronto Stock Exchange18.35
CAD
-0.32
- -
Helius Medical Technologies, Inc.
HSM.TO
(Toronto Stock Exchange)
Recent
price
18.35
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Helius Medical Technologies, Inc. is a neurotechnology company specializing in non-invasive therapeutic neuromodulation devices designed to improve neurological deficits related to balance and gait. The company's core product is the Portable Neuromodulation Stimulator (PoNS), a device that stimulates cranial nerves via tongue-based stimulation, intended for patients with conditions such as Multiple Sclerosis (MS) and mild-to-moderate Traumatic Brain Injury (TBI). PoNS therapy combines the device with supervised physical or cognitive exercises and requires prescription and certified therapist administration. Helius operates primarily in North America including the United States and Canada, targeting medical professionals and patients in neurological rehabilitation segments. Founded in 2006 and headquartered in Newtown, Pennsylvania, the company focuses on amplifying the brain’s ability to heal itself through neuroplasticity. Recently, Helius has undergone significant transformations including a rebranding to Solana Company, reflecting an expansion into digital asset treasury management alongside its core medical technology operations. In 2025, it executed a $500 million private investment in public equity (PIPE) financing to support this strategic diversification. The company has also established strategic partnerships, notably with Lovell Government Services to expand PoNS therapy access within U.S. federal healthcare systems including the Department of Veterans Affairs, highlighting efforts to increase market penetration in major institutional healthcare providers. Regulatory progress includes receiving Medicare HCPCS codes for PoNS components and securing preliminary Medicare reimbursement coverage, which marks a critical step for commercial adoption and revenue growth. Additionally, Helius executed a 1-for-50 reverse stock split to optimize its stock structure during its market expansion phase. Helius Medical Technologies operates within the neurotechnology and medical device industry, uniquely positioning its PoNS therapy as a non-invasive alternative in neurological rehabilitation. The company continues to focus on strengthening its commercial footprint within the specialized market for treating gait and balance deficits related to neurological disorders. It leverages ongoing clinical collaborations, regulatory advances, and innovative financings to drive growth. The company is listed on NASDAQ under the ticker HSDT and maintains a strategy emphasizing both cutting-edge medical device innovation and newer initiatives in digital asset management through its Solana rebranding and treasury strategy.